AD 4

Drug Profile

AD 4

Alternative Names: L-2-Acetamido-3-mercaptopropionamide; N-Acetylcysteinamide; N-Acetylcysteine amide; AD-4; NACA

Latest Information Update: 24 Jan 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer Eucalyptus Ltd; Yissum Research Development Company
  • Class Eye disorder therapies; Neuroprotectants; Small molecules; Sulfhydryl compounds
  • Mechanism of Action Antioxidants; Chelating agents; Free radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Neurodegenerative disorders

Most Recent Events

  • 09 Jan 2008 Preclinical trials in Neurodegenerative disorders in USA (PO)
  • 09 Jan 2008 AD 4 exclusively licensed to Eucalyptus Ltd. worldwide for the treatment of Neurodegenerative disorders
  • 24 Apr 2007 No development reported - Preclinical for Neuroprotection in Israel (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top